Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Alison P. Klein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2737-8399; OpenAlex author ID A5029218403; NIH RePORTER profile ID 2093747. Sources: ClinicalTrials.gov.

Their work

Papers
93 (first author 9, last author 13)
Trials
1 (principal investigator on 1)
Grants
6
Labs led
1
Collaborators
279
Papers, trials and grants by year

1994: 1 trial · 1995: none · 1996: none · 1997: none · 1998: none · 1999: none · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: 7 papers · 2013: 5 papers · 2014: 3 papers · 2015: 8 papers · 2016: 5 papers · 2017: 4 papers · 2018: 5 papers · 2019: 5 papers · 2020: 11 papers, 1 grant · 2021: 14 papers · 2022: 7 papers, 2 grants · 2023: 5 papers · 2024: 5 papers · 2025: 3 papers, 1 grant · 2026: 4 papers, 2 grants

Papers 50 of 93

  1. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  2. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  3. Targeting RAS for Pancreatic Cancer Interception. Co-author DOI 10.1158/2159-8290.cd-26-1179↗
  4. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Last author DOI 10.64898/2026.04.21.26351329↗
  5. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  6. Impact of race, sex and age on the probability of pancreatic cancer among patients with newly diagnosed diabetes in a claims-based cohort. Last author DOI 10.1136/bmjopen-2025-099488↗
  7. Why Is Earlier Detection, the Key to Reducing Pancreatic Cancer, So Challenging Despite Technological Advances? First author DOI 10.1200/jco-25-00796↗
  8. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  9. Understanding familial risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10689-024-00383-2↗
  10. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  11. The Pivotal Role of Germline BRCA2 Pathogenic Variants in "Apparently Sporadic" Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-24-2730↗
  12. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Last author DOI 10.1158/1055-9965.epi-24-0096↗
  13. Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study. First author DOI 10.1002/cam4.5094↗
  14. Screening for pancreatic cancer has the potential to save lives, but is it practical? Co-author DOI 10.1080/17474124.2023.2217354↗
  15. Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor (FUT2) Genotype, but Not Lewis Antigen (FUT3) Genotype. Co-author DOI 10.1158/1055-9965.epi-23-0009↗
  16. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  17. Feasibility of the Genetic Information Assistant Chatbot to Provide Genetic Education and Study Genetic Test Adoption Among Pancreatic Cancer Patients at Johns… First author PMID 37350913↗
  18. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. Co-author DOI 10.1002/ijc.33883↗
  19. Familial pancreatic cancer: who should be considered for genetic testing? Co-author DOI 10.1007/s11845-021-02572-9↗
  20. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  21. Pancreatic Adenocarcinoma: Trends in Epidemiology, Risk Factors, and Outcomes. First author DOI 10.1016/j.hoc.2022.07.002↗
  22. Endoplasmic stress-inducing variants in carboxyl ester lipase and pancreatic cancer risk. Co-author DOI 10.1016/j.pan.2022.08.004↗
  23. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Last author DOI 10.1093/jnci/djac167↗
  24. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  25. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Last author DOI 10.1001/jamaoncol.2021.3701↗
  26. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants. Co-author DOI 10.1002/gcc.22947↗
  27. A pooled genome-wide association study identifies pancreatic cancer susceptibility loci on chromosome 19p12 and 19p13.3 in the full-Jewish population. First author DOI 10.1007/s00439-020-02205-8↗
  28. Pancreatic cancer pathology viewed in the light of evolution. Co-author DOI 10.1007/s10555-020-09953-z↗
  29. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  30. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  31. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.03.015↗
  32. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Last author DOI 10.1038/s41416-021-01580-x↗
  33. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Co-author DOI 10.1038/s41575-021-00457-x↗
  34. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  35. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001888↗
  36. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  37. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Co-author DOI 10.1158/1940-6207.capr-20-0642↗
  38. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  39. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  40. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  41. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  42. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. Co-author DOI 10.1093/jnci/djaa004↗
  43. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  44. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  45. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  46. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Co-author DOI 10.1158/1055-9965.epi-19-1389↗
  47. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0091↗
  48. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  49. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  50. Screening for Pancreatic Cancer—Is There Hope? Last author DOI 10.1001/jamainternmed.2019.3323↗

Trials 1

  1. Pancreatic Cancer Registry: For Any Person With a Personal or Family History Principal investigator NCT02886247↗

Grants 6

  1. Cancer Prevention and Control Program P30CA006973↗
  2. Improving Management of patients at High Risk of Pancreatic Cancer R01CA299421↗
  3. Multi-Ancestry Mapping of Pancreatic Cancer Susceptibility Loci U01CA247283↗
  4. Early Events in Pancreatic Cancer Grant: Alison Klein (high-risk pancreatic cancer genes) AWARD lustgarten:2022-alison-klein-phd-mhs-early-events-in-pancreatic-cancer-grant-
  5. Core 2: Biospecimen/Pathology Core P50CA062924↗
  6. Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study) R01CA154823↗

Closest collaborators

The 25 strongest of 279 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 33 shared papers, 1 shared grant, 2011–2025 · strength 3.27
  2. Ralph H. Hruban · 35 shared papers, 1 shared grant, 2011–2024 · strength 3.07
  3. Nicholas Jason Roberts · 23 shared papers, 2012–2024 · strength 2.46
  4. Nickolas Papadopoulos · 4 shared papers, 1 shared grant, 2012–2026 · strength 1.41
  5. Anne Marie Lennon · 10 shared papers, 1 shared grant, 2014–2024 · strength 1.36
  6. Marcia Irene Canto · 13 shared papers, 2012–2024 · strength 1.29
  7. Zaver M. Bhujwalla · 1 shared grant, 2026 · strength 1.26
  8. Jin Peng He · 12 shared papers, 2017–2024 · strength 1.19
  9. Gloria M. Petersen · 16 shared papers, 2012–2024 · strength 1.08
  10. Sapna Syngal · 13 shared papers, 2012–2024 · strength 1.00
  11. Steve Gallinger · 14 shared papers, 2012–2022 · strength 0.99
  12. Laura DeLong Wood · 4 shared papers, 2016–2026 · strength 0.86
  13. Elliot K. Fishman · 9 shared papers, 2013–2024 · strength 0.82
  14. Elizabeth M. Jaffee · 3 shared papers, 1 shared grant, 2016–2026 · strength 0.79
  15. Daniel A. Laheru · 10 shared papers, 2011–2022 · strength 0.76
  16. Christopher Lee Wolfgang · 13 shared papers, 2012–2022 · strength 0.76
  17. Richard Andrew Burkhart · 7 shared papers, 2020–2024 · strength 0.75
  18. Harvey A. Risch · 7 shared papers, 2016–2023 · strength 0.70
  19. James R. Eshleman · 10 shared papers, 2011–2023 · strength 0.70
  20. Laufey Thora Amundadottir · 7 shared papers, 2016–2023 · strength 0.69
  21. Elham Afghani · 2 shared papers, 2022–2025 · strength 0.66
  22. Amanda L. Blackford · 6 shared papers, 2018–2024 · strength 0.64
  23. Anirban Maitra · 3 shared papers, 1 shared grant, 2011–2024 · strength 0.54
  24. Jeanine M. Genkinger · 1 shared paper, 2025 · strength 0.54
  25. Randall E. Brand · 7 shared papers, 2016–2024 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.